Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avita Medical (RCEL)
NASDAQ:RCEL
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.32Last Year’s EPS
-0.73Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 13, 2025
|% Change Since: 11.05%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Neutral
AVITA Medical's earnings call reflected a transformative year with substantial revenue growth, improved gross profit margins, and a significant increase in total addressable market due to new product launches. However, the company faced challenges with a Q4 revenue shortfall, increased net losses, and higher operating expenses, which balanced the positive achievements.Company Guidance
During AVITA Medical's fourth quarter 2024 earnings call, they provided guidance for 2025, projecting commercial revenue to be in the range of $100 million to $106 million, representing a growth of 55% to 65% compared to 2024. The company anticipates generating free cash flow in the second half of 2025 and achieving GAAP profitability during Q4 of 2025. The guidance reflects contributions from new product launches, including RECELL GO mini and Cohealyx, which are expected to significantly impact revenue growth. Additionally, AVITA Medical plans to expand RECELL GO adoption and roll out PermeaDerm, with expectations of gaining CE mark approval for RECELL GO in the European Union by mid-year, further expanding their market opportunities. The company's focus remains on therapeutic acute wound care, and they aim to enhance clinical outcomes while reducing healthcare costs.Strong Revenue Growth
AVITA Medical reported a 30% increase in commercial revenue for Q4 2024 compared to the same period in 2023, driven by the continued deployment and adoption of RECELL GO, and new accounts in trauma centers.
Portfolio Expansion and Market Potential
The launch of new products, including RECELL GO mini, PermeaDerm, and Cohealyx, expanded the total addressable market (TAM) from $500 million to $3.5 billion in the U.S. alone.
Improved Gross Profit Margin
Q4 2024 gross profit margin improved to 87.6%, slightly increasing from 87.3% in the same period of 2023.
Significant TAM Increase
The company expanded its TAM from $500 million two years ago to $3.5 billion, largely due to portfolio expansion into trauma centers.
Positive Clinical Outcomes for Cohealyx
Early clinical use of Cohealyx showed promising results, reducing hospital stays significantly, as highlighted by a case where a patient's hospital stay was reduced from a month to 1.5 weeks.
---
RCEL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RCEL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 13, 2025 | $8.78 | $10.57 | +20.39% |
| Nov 07, 2024 | $12.40 | $11.95 | -3.63% |
| Aug 08, 2024 | $7.93 | $9.57 | +20.68% |
| May 13, 2024 | $8.35 | $8.72 | +4.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Avita Medical (RCEL) report earnings?
Avita Medical (RCEL) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Avita Medical (RCEL) earnings time?
Avita Medical (RCEL) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RCEL EPS forecast?
RCEL EPS forecast for the fiscal quarter 2025 (Q1) is -0.32.
---